Do You Like Baxter International Inc. (NYSE:BAX) At This P/E Ratio?

Today, we’ll introduce the concept of the P/E ratio for those who are learning about investing. We’ll apply a basic P/E ratio analysis to Baxter International Inc.’s (NYSE:BAX), to help you decide if the stock is worth further research. Baxter International has a P/E ratio of 28.53, based on the last twelve months. In other words, at today’s prices, investors are paying $28.53 for every $1 in prior year profit.

Check out our latest analysis for Baxter International

How Do You Calculate Baxter International’s P/E Ratio?

The formula for P/E is:

Price to Earnings Ratio = Price per Share ÷ Earnings per Share (EPS)

Or for Baxter International:

P/E of 28.53 = $86.97 ÷ $3.05 (Based on the year to June 2019.)

Is A High P/E Ratio Good?

A higher P/E ratio implies that investors pay a higher price for the earning power of the business. That isn’t necessarily good or bad, but a high P/E implies relatively high expectations of what a company can achieve in the future.

Does Baxter International Have A Relatively High Or Low P/E For Its Industry?

We can get an indication of market expectations by looking at the P/E ratio. The image below shows that Baxter International has a lower P/E than the average (40.6) P/E for companies in the medical equipment industry.

NYSE:BAX Price Estimation Relative to Market, August 21st 2019
NYSE:BAX Price Estimation Relative to Market, August 21st 2019

Baxter International’s P/E tells us that market participants think it will not fare as well as its peers in the same industry.

How Growth Rates Impact P/E Ratios

Companies that shrink earnings per share quickly will rapidly decrease the ‘E’ in the equation. Therefore, even if you pay a low multiple of earnings now, that multiple will become higher in the future. Then, a higher P/E might scare off shareholders, pushing the share price down.

In the last year, Baxter International grew EPS like Taylor Swift grew her fan base back in 2010; the 79% gain was both fast and well deserved. Regrettably, the longer term performance is poor, with EPS down -8.7% per year over 3 years.

Remember: P/E Ratios Don’t Consider The Balance Sheet

The ‘Price’ in P/E reflects the market capitalization of the company. Thus, the metric does not reflect cash or debt held by the company. The exact same company would hypothetically deserve a higher P/E ratio if it had a strong balance sheet, than if it had a weak one with lots of debt, because a cashed up company can spend on growth.

Such expenditure might be good or bad, in the long term, but the point here is that the balance sheet is not reflected by this ratio.

So What Does Baxter International’s Balance Sheet Tell Us?

Net debt totals just 5.0% of Baxter International’s market cap. So it doesn’t have as many options as it would with net cash, but its debt would not have much of an impact on its P/E ratio.

The Verdict On Baxter International’s P/E Ratio

Baxter International trades on a P/E ratio of 28.5, which is above its market average of 17.3. Its debt levels do not imperil its balance sheet and its EPS growth is very healthy indeed. So on this analysis a high P/E ratio seems reasonable.

When the market is wrong about a stock, it gives savvy investors an opportunity. As value investor Benjamin Graham famously said, ‘In the short run, the market is a voting machine but in the long run, it is a weighing machine.’ So this free visual report on analyst forecasts could hold the key to an excellent investment decision.

Of course, you might find a fantastic investment by looking at a few good candidates. So take a peek at this free list of companies with modest (or no) debt, trading on a P/E below 20.

We aim to bring you long-term focused research analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material.

If you spot an error that warrants correction, please contact the editor at editorial-team@simplywallst.com. This article by Simply Wall St is general in nature. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Simply Wall St has no position in the stocks mentioned. Thank you for reading.